Mzb1 protects against myocardial infarction injury in mice via modulating mitochondrial function and alleviating inflammation

• 作者: Lu Zhang Yi-ning Wang Jia-ming Ju Azaliia Shabanova Yue Li Ruo-nan Fang Jia-bin Sun Ying-ying Guo Tong-zhu Jin Yan-yan Liu Tian-yu Li Hong-li Shan Hai-hai Liang Bao-feng Yang
• 来源期刊: 中国药理学报（英文版）
• 年，卷（期）: 2021,（5）
• 所属期刊栏目: Cardiovascular Pharmacology
• 页码范围: 691-700
• 页数: 10页
• 语种: 英文

摘要

Myocardial infarction (MI) leads to the loss of cardiomyocytes,left ventricle dilation and cardiac dysfunction,eventually developing into heart failure.Mzb1 (Marginal zone B and B1 cell specific protein 1) is a B-cell-specific and endoplasmic reticulum-localized protein.Mzb1 is an inflammation-associated factor that participates a series of inflammatory processes,including chronic periodontitis and several cancers.In this study we investigated the role of Mzb1 in experimental models of MI.MI was induced in mice by ligation of the left descending anterior coronary artery,and in neonatal mouse ventricular cardiomyocytes (NMVCs) by H2O2 treatment in vitro.We showed that Mzb1 expression was markedly reduced in the border zone of the infarct myocardium of MI mice and in H2O2-treated NMVCs.In H2O2-treated cardiomyocytes,knockdown of Mzb1 decreased mitochondrial membrane potential,impaired mitochondrial function and promoted apoptosis.On contrary,overexpression of Mzb1 improved mitochondrial membrane potential,ATP levels and mitochondrial oxygen consumption rate (OCR),and inhibited apoptosis.Direct injection of lentiviral vector carrying Len-Mzb1 into the myocardial tissue significantly improved cardiac function and alleviated apoptosis in MI mice.We showed that Mzb1 overexpression significantly decreased the levels of Bax/Bcl-2 and cytochrome c and improved mitochonddal function in MI mice via activating the AMPK-PGC1o pathway.In addition,we demonstrated that Mzb1 recruited the macrophages and alleviated inflammation in MI mice.We conclude that Mzb1 is a crucial regulator of cardiomyocytes after MI by im proving mitochondrial function and reducing inflammatory signaling pathways,implying a promising therapeutic target in ischemic cardiomyopathy.